Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluatin

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results/StudyNewron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia 16.02.2023 / 07:00 CET/CESTThe issuer is solely responsible...

Related Keywords

Seika ,Kyongsang Bukto ,South Korea ,Australia ,Japan ,Milan ,Lombardia ,Italy ,United States ,Paris ,France General ,France ,United Kingdom ,United Arab Emirates ,Canada ,Toronto ,Ontario ,Sri Lanka ,Germany ,Bresso ,India ,Israel ,Switzerland ,America ,Swiss ,Ravi Anand ,Anne Hennecke Caroline Bergmann ,Paul Sagan ,Stefan Weber ,Valentin Handschin ,Jean Pierre Lindenmayer ,Mc Services ,European Congress ,Schizophrenia International Research Society ,Newron Pharmaceuticals ,Swiss Exchange ,Distribution Services ,Psychopharmacology Research Unit ,European Union ,Supernus Pharmaceuticals ,Negative Syndrome Scale ,Kline Institute ,Psychiatric Research ,Manhattan Psychiatric Center ,Independent Safety Monitoring Board ,Chief Medical Officer ,Clinical Global Impression ,Strauss Carpenter Level ,Latin America ,Meiji Seika ,Ciara Martin ,Natalie Garland Collins ,Caroline Bergmann ,Corporate News ,Regulatory Announcements ,